Peak Retirement Planning Inc. Acquires New Shares in Elanco Animal Health Incorporated $ELAN

Peak Retirement Planning Inc. acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 121,770 shares of the company’s stock, valued at approximately $2,756,000.

Several other institutional investors also recently modified their holdings of the business. Natixis Advisors LLC purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at $984,000. Root Financial Partners LLC boosted its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at $395,000. BNP Paribas Financial Markets boosted its position in shares of Elanco Animal Health by 3,682.0% during the fourth quarter. BNP Paribas Financial Markets now owns 2,252,961 shares of the company’s stock valued at $50,985,000 after buying an additional 2,193,391 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at $32,415,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 0.1%

Shares of NYSE:ELAN opened at $23.65 on Wednesday. The stock has a market capitalization of $11.81 billion, a price-to-earnings ratio of -47.30, a PEG ratio of 2.55 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock’s 50-day simple moving average is $22.93 and its two-hundred day simple moving average is $23.33. Elanco Animal Health Incorporated has a 52-week low of $13.14 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same period last year, the firm posted $0.37 earnings per share. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Insider Activity

In related news, CEO Jeffrey N. Simmons acquired 4,971 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several recent analyst reports. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Morgan Stanley raised their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. KeyCorp raised their target price on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.